Neurent Medical secures $25m growth investment for NEUROMARK expansion
The funding supports commercial expansion of the company’s minimally invasive treatment for chronic rhinitis.
Treating chronic rhinitis at its source
Neurent Medical’s NEUROMARK system uses impedance-controlled radiofrequency energy to target hyperactive nerves at the back of the nose. The minimally invasive procedure is designed to provide durable relief for people with chronic rhinitis.
The company is moving into commercial expansion with a $25 million growth investment from Claret Capital Partners. Its funding plans include sales and marketing as well as balance-sheet support for future growth, extending the reach of a treatment built around a specific nerve target rather than ongoing symptom management.
Use of funds
Commercial expansion
Sales and marketing
Fund the balance sheet and future growth